Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib

Legros L, Guilhot J, Huault S, Mahon FX, Preudhomme C, Guilhot F, Hueber A (2014)

Publication Type: Journal article

Publication year: 2014

Journal

Leukemia Research Elsevier

Book Volume: 38

Pages Range: 662-5

Journal Issue: 6

DOI: 10.1016/j.leukres.2014.01.010

Abstract

In chronic myeloid leukemia (CML), evidence is supporting the role of VEGF in growth, and survival of leukemia cells. The evaluation of plasma VEGF levels in 403 CML patients randomized within SPIRIT study to received imatinib-400mg versus imatinib+cytarabine versus imatinib+interferon (IFN) versus imatinib-600mg demonstrated that VEGF is an independent factor of BCR-ABL burden. VEGF low levels at diagnosis were associated with a progression-free survival of 100% at 48 months. Under treatment, significant lowest levels were observed in imatinib+IFN arm. These results support the use of VEGF as a parameter to predict CML evolution and let us to speculate about antiangiogenic properties of IFN.

Authors with CRIS profile

Axel Hueber Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Hôpital l'Archet (CHU de Nice)

France (FR) National Center for Scientific Research / Centre national de la recherche scientifique (CNRS)

France (FR) Bordeaux 2 Segalen University

France (FR) Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille)

France (FR) Centre hospitalier universitaire de Poitiers (CHU de Poitiers)

France (FR)

How to cite

APA:

Legros, L., Guilhot, J., Huault, S., Mahon, F.X., Preudhomme, C., Guilhot, F., & Hueber, A. (2014). Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. Leukemia Research, 38(6), 662-5. https://doi.org/10.1016/j.leukres.2014.01.010

MLA:

Legros, L., et al. "Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib." Leukemia Research 38.6 (2014): 662-5.

BibTeX: Download